Tag: 3 best Canadian Biotech companies
-
Medexus Pharmaceuticals (MDP.V), Flexing its deal making muscles
Buckle up everyone, and get excited – let’s break down Medexus’ latest press release with all its technical details. This is a two-parter, because Medexus not only has closed an important deal that has relevancy for blood cancer treatments, but it’s also upsized its current financing – a financial move that’s indicative of the growing…
-
Does Core One Labs (COOL.C) have a solution for psilocybin’s dosing problem?
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and addictions.
-
Can scrappy Valeo Pharma (VPH.C) win a Stanley Cup?
“With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives,” stated Saviuk.
-
![That was quick: Valeo Pharma (VPH.C) gets Health Canada nod for immune system booster]()
That was quick: Valeo Pharma (VPH.C) gets Health Canada nod for immune system booster
“There is a strong scientific and medical rationale for the use of Hesperco capsules to support the immune system,” stated Pierre Laurin, CEO of Ingenew, who added that it could “potentially fight off symptoms associated with coronaviruses.”
-
Valeo Pharma Inc. (VPH.C) – THE undervalued biotech play
If you’re one of the discerning readers who bought Valeo Pharma’s stock since the last article I posted on July 6th, 2020: congratulations you should be making over 38% returns on your investment. Better yet, if you had bought Valeo’s stock a month ago, you would have been up close to 184%, which, y’know, is…
-
Biohaven (BHVN.NYSE), Zosano Pharma (ZSAN.Q), Lundbeck (HLUYY.OTC) tackle a $41 billion problem that cruelly targets women
“More than 4 million adults experience chronic daily migraine – with at least 15 migraine days per month,” states The Migraine Research Foundation, “It affects 39 million people in the U.S. and 1 billion worldwide.”
-
![vTv Therapeutics (VTVT.Q) surges 55% on type 1 diabetes drug trial]()
vTv Therapeutics (VTVT.Q) surges 55% on type 1 diabetes drug trial
“A once-a-day pill that reduces HbA1c and improves time in range with continuous glucose monitoring, without increasing hypoglycemia or any signal for adverse events, is a big win for the future care of type 1 diabetes,” stated clinical researcher Dr. John Buse.
-
![Resverlogix (RVX.T), Sirona Biochem (SBM.V), Sernova (SVA.V): 3 Canadian biotechs tackle a $330 billion health crisis]()
Resverlogix (RVX.T), Sirona Biochem (SBM.V), Sernova (SVA.V): 3 Canadian biotechs tackle a $330 billion health crisis
A Harvard University Study calculates the economic burden from diabetes at about $1.3 trillion, or 1.8% of global GDP.
